---
run_id: halo-evidence-vs-diagnosis-validation-v12-vanilla-05
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
model_condition: vanilla
run_number: 5
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 2048
seed: 501
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
condition_packet_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
output_file: model-outputs/vanilla-05.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 05)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v12-v1`, condition `vanilla`, run 5 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 501, on the frozen condition packet.

## Output

I recommend the **Case Evidence Review**.

### The Recommendation
You should recommend the Case Evidence Review to the CEO.

While your executive team is celebrating "commercial discipline," the evidence suggests you have a **correlation problem**, not a product-market fit victory. Your revenue growth is currently driven by pricing incentives (bundle discounts) and sales narratives (the roadmap pitch), not necessarily the inherent value of the tool.

The Case Evidence Review is the only option that penetrates the "entangled" evidence to find the ground truth. By analyzing whether suggestions were accepted, overridden, or impossible to explain, you determine if PlanPilot is solving a core workflow pain point or simply providing a "draft" that analysts then manually fix. This distinguishes between **usage** (which is currently inflated by managers rerunning samples) and **utility** (whether the product actually reduces manual labor for the front-line analyst).

### The Strongest Reason Against It
The Case Evidence Review is a "slow" qualitative signal in a high-pressure quantitative environment. The CEO and Board are currently riding a wave of 16% expansion growth; recommending a manual audit of case files may be perceived as "product perfectionism" or an attempt to find problems where the sales team is already finding money. It does not provide the immediate, scalable "green light" that a Demand Cleanroom or Adoption Sprint would offer to justify a massive budget increase.

### The Evidence That Would Change My Mind
I would pivot to the **Demand Cleanroom** if you discover that the "impossible to explain" feedback in the public sector is a regulatory requirement rather than a UX failure.

If the barrier to adoption is legally mandated transparency (i.e., analysts *cannot* use a "black box" recommendation regardless of its accuracy), then the product is fundamentally broken for that segment. In that scenario, you no longer need to know *if* the tool works (Case Evidence); you need to know if your current pricing and pitching strategy is masking a systemic lack of demand from the actual users.
